MapLight Therapeutics, Inc.
MPLT Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$7.66
KIRA · Stoqly’s AI analyst, in plain words
- MapLight Therapeutics, Inc. lost $161M in fiscal 2025.
- Free cash flow was −$139M in fiscal 2025, — of revenue.
Market cap
$348M
P/E
0.2x
Revenue
—
Net income
−$161M
Free cash flow
−$139M
Operating margin
—
MapLight Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$161M
No. It lost money last year.
How is the share priced?
0.2x
One share costs 0.2 times its yearly profit per share.
What MapLight Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- MapLight Therapeutics, Inc.
- CIK
- 0001770069
MapLight Therapeutics, Inc. · MPLT
Results and finances
The last 2 fiscal years. Amounts in USD.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Sales and profit | ||
| Net income | −$77.6M | −$161M |
| Diluted EPS | −$105.38 | −$18.56 |
| Cash | ||
| Cash from operations | −$78.8M | −$138M |
| Capital expenditure | $0.8M | $0.5M |
| Free cash flow | −$79.6M | −$139M |
| Share count change | — | 1,079.1% |
| Debt and strength | ||
| Cash and short-term investments | $109M | $305M |
| Shareholders' equity | −$194M | $458M |
| Current ratio | 7.2x | 20.0x |
| Returns and quality | ||
| Return on equity | — | −121.7% |
| Return on tangible equity | — | −35.2% |
| Altman Z'' | −13.5 | 22.2 |
Insiders bought, 12 months
$175M
5 insiders
Insiders sold, 12 months
$30.2M
8 insiders
Of sales under plans
66%
$20.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
MapLight Therapeutics, Inc. · MPLT
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.66 a share, the company is worth $348M: 0.2 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001770069). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.